OTCM
CUVL
Market cap262mUSD
Oct 19, Last price
5.24USD
1D
0.10%
1Q
-25.36%
Jan 2017
-0.95%
IPO
-29.66%
Name
Clinuvel Pharmaceuticals Ltd
Chart & performance
P/E
10.47
P/S
3.99
EPS
0.72
Div yield, %
0.63%
Shs. 5Y
-0.03%
Rev. 5Y
23.88%
Revenues
95m
+7.76%
Net income
36m
+1.50%
CFO
41m
+10.91%
Dividend
Sep 08, 20260.035555 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Key people
Jeffrey Rosenfeld
Non-Executive Chairman of the Board · since 2024
Peter Vaughan
Chief Financial Officer · since 2024
Lachlan Hay
Acting Chief Executive Officer, Chief Operating Officer · since 2025
Dennis Wright
Chief Scientific Officer · since 2020
Antonella Colucci
Vice President - Commercial Affairs · since 2024
Malcolm Bull
Head of Australian Operations and Investor Relations · since 2024
Azza Hamila
Head of Quality Assurance and Drug Safety · since 2024
Emilie Rodenburger
Director - Global Clinical Affairs · since 2024
David Soloman
Head of Regulatory Affairs · since 2025
Linda Teng
Director of North American Operations · since 2024
Claire Newstead-Sinclair
Company Secretary · since 2024
Pearl Grimes
Non-Executive Director · since 2024
Matthew Pringle
Non-Executive Director · since 2024
Guy Van Dievoet
Non-Executive Director · since 2024
Karen Agersborg
Non-Executive Independent Director · since 2019
Susan Smith
Non-Executive Independent Director · since 2019
Headquarters & legal address
Level 22, 535 Bourke Street
Melbourne, VIC 3000
AU
Melbourne, VIC 3000
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||